Ulf Henrik M.
- Country
- Sweden
- Department
- Medicinmottagningen, Södra Älvsborgs Sjukhus Borås
Research Overview
- Persistence of Remission Following Discontinuation of BCMA-CD3 Bispecific Antibodies in Multiple Myeloma Patients With Major M-Spike Response
- Phase 1/2 Open‑Label Study of Oral Surzetoclax Monotherapy and Surzetoclax plus Etentamig Combination in Relapsed/Refractory Biomarker‑Selected Multiple Myeloma
- Evaluation of Ixekizumab on Endogenous Insulin Preservation in Newly Diagnosed Type 1 Diabetes: A Randomized, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 123 of 253 partner sites.
Specializations
Multiple Myeloma Treatment
This investigator specializes in researching innovative therapies for multiple myeloma, with particular focus on both newly diagnosed and relapsed/refractory cases.
- Novel therapeutic combinations
- Post-transplant maintenance strategies
- Targeted immunotherapy approaches
The research encompasses various treatment modalities including monoclonal antibodies and immunomodulatory agents.
Blood Cancer Innovation
The investigator conducts research in advanced therapeutic strategies for hematologic malignancies, particularly focusing on treatment-resistant forms.
- Drug administration optimization
- Comparative treatment efficacy
- Alternative delivery methods
Expertise includes evaluation of subcutaneous versus intravenous administration routes for cancer therapeutics.
Autoimmune Conditions
The investigator explores treatments for autoimmune disorders, with specific attention to type 1 diabetes management and intervention.
- Early intervention strategies
- Insulin secretion preservation
- Novel biological therapies
Research focuses on therapeutic approaches for newly diagnosed autoimmune conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.